AskBorsa

Ibnsina Pharma results, Q3 2026

Net profit, assets, equity and cash flow for Q3 2026, against the same period a year earlier, from the published financial statements. Consolidated figures cover the 9 months to 30 September 2026; the comparison is with the same months a year earlier, from the same disclosure.

Net profit909 millionEGP · +37.7% vs the same period a year earlier
Total assets44.69 billionEGP · +23.4% vs the same period a year earlier
Shareholders' equity3.38 billionEGP · +21.3% vs the same period a year earlier
Operating cash flow877 millionEGP · +8772.5% vs the same period a year earlier

In short

  • Ibnsina Pharma's net profit for Q3 2026 was about 909 million EGP, up +37.7% from 660 million EGP in Q3 2025.
  • Total assets at the end of Q3 2026 were about 44.69 billion EGP, and shareholders' equity about 3.38 billion EGP.
  • Operating cash flow for Q3 2026 was positive at 877 million EGP.
Source: the Q3 2026 financial statements, read from the published report

Key lines against the same period a year earlier

This periodQ3 2025Change
Net profit909 million660 million+37.7%
Gross profit5.3 billion4.74 billion+11.9%
Total assets44.69 billion36.21 billion+23.4%
Total liabilities41.32 billion33.43 billion+23.6%
Shareholders' equity3.38 billion2.78 billion+21.3%
Operating cash flow877 million9.89 million+8772.5%

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Consolidated figures cover the 9 months to 30 September 2026; the comparison is with the same months a year earlier, from the same disclosure.

Official report (PDF)All of Ibnsina Pharma's statements, five yearsAsk the AI analyst about ISPH

Ibnsina Pharma's Fiscal year 2026 results, the day they are published

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

Other periods for Ibnsina Pharma